BCR signaling can activate PI3K and pharmacological targeting of PI3K (e.g., idelalisib) is also a therapeutic strategy in chronic lymphocytic leukemia [54, 55], though current use of PI3Ki in CLL is diminishing due to undue toxicities and lesser efficacy. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.